This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE * cardiovascular (CV) death, myocardial infarction…
- Investigator
- Carl J Pepine
- Ages
- 18 Years - N/A
- Sexes
- All